Delving into the Latest Updates on Centro Nacional de Investigaciones Oncologicas with Synapse

概览

疾病领域	数量

肿瘤	2
血液及淋巴系统疾病	1
免疫系统疾病	1

排名前五的药物类型	数量

小分子化药	2
腺相关病毒基因治疗	1

排名前五的靶点	数量

Class I PI3K(磷脂酰肌醇激酶I型复合体)	1
PIM1(Pim-1 激酶)	1

关联

5

项与 Centro Nacional de Investigaciones Oncologicas 相关的药物

ETP-46992

靶点

Class I PI3K

作用机制

Class I PI3K抑制剂

在研机构

Centro Nacional de Investigaciones Oncologicas

原研机构

Centro Nacional de Investigaciones Oncologicas

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

AAV9-tert gene therapy (CNIO/Universitat Autonoma de Barcelona/F Hoffmann-La Roche)

靶点-

作用机制

基因转移

在研机构

F. Hoffmann-La Roche Ltd. [+2]

原研机构

Centro Nacional de Investigaciones Oncologicas

在研适应症

再生障碍性贫血 [+2]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

IBL-100

靶点

PIM1

作用机制

PIM1抑制剂

在研机构

Centro Nacional de Investigaciones Oncologicas [+1]

原研机构

Centro Nacional de Investigaciones Oncologicas

在研适应症

自身免疫性疾病 [+2]

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与 Centro Nacional de Investigaciones Oncologicas 相关的临床结果

登录后查看更多信息

0 项与 Centro Nacional de Investigaciones Oncologicas 相关的专利（医药）

登录后查看更多信息

2,972

项与 Centro Nacional de Investigaciones Oncologicas 相关的文献（医药）

2025-12-31·OncoImmunology

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers

Article

作者: Díez-Alonso, Laura ; Álvarez-Vallina, Luis ; Arroyo-Ródenas, Javier ; Velasco-Sidro, Miriam ; Ramírez-Fernández, Ángel

Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T), there is still an important number of patients experiencing refractory/relapsed (R/R) disease. Approaches to avoid tumor-intrinsic mechanisms of resistance such as immune pressure-mediated antigen downmodulation, are being broadly investigated. These strategies include BCMA/CD19 dual-targeting therapies, which may be of particular interest to patients with B cell lymphoma and multiple myeloma, where a specific double-positive immature subpopulation is commonly associated with poor prognosis and poor response to current treatments. In fact, several clinical trials targeting both antigens through different strategies are currently underway. Here, based on the previously validated STAb (in situ secretion of T cell-redirecting bispecific antibodies) concept, we used two different engineering strategies (pool and co-transduction) to generate dual-targeted STAb-T cells simultaneously secreting BCMA TCE and CD19 TCE that outperformed single-targeted STAb-T cells in different in vitro models. These promising results encourage further preclinical clinical testing of dual STAb-T cells in R/R B-cell malignancies.

2025-01-17·Clinical Cancer Research

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

Article

作者: Muthuswamy, Senthil K. ; Hidalgo, Manuel ; Guerra, Carmen ; Feliu, Jaime ; Alonso, Carolina ; López-Acosta, José Francisco ; Sarno, Francesca ; Lapunzina, Pablo ; Guillen-Ponce, Carmen ; Esquivel, Estrella ; Pazo-Cid, Roberto ; Juez, Ignacio ; Medina, Laura ; Bockorny, Bruno ; Garcia-Carbonero, Rocío ; Perea, Sofia ; Akshinthala, Dipikaa ; Dopazo, Ana ; Lopez-Casas, Pedro P. ; Tenorio, Jair ; Duran, Yolanda

AbstractPurpose:Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options. We compared the efficacy of comprehensive precision medicine against that of the conventional treatment in PDAC.Patients and Methods:We report a phase III trial of advanced PDAC in which patients were randomized (1:2) to a conventional treatment treated at physician’s discretion (arm A) or to precision medicine (arm B). Subjects randomized to arm B underwent a tumor biopsy for whole-exome sequencing and to generate avatar mouse models and patient-derived organoids for phenotypic drug screening, with final treatment recommended by the molecular tumor board. The primary objective was median overall survival (OS).Results:A total of 137 patients were enrolled with 125 randomized, 44 to arm A and 81 to arm B. Whole-exome sequencing was performed in 80.3% (65/81) patients of arm B, with potentially actionable mutations detected in 21.5% (14/65). Experimental models were generated in 16/81 patients (19.8%). Second-line treatment was administered to 39 patients in the experimental arm, but only four (10.2%) received personalized treatment, whereas 35 could not receive matched therapy because of rapid clinical deterioration, delays in obtaining study results, or the absence of actionable targets. The median OS was 8.7 and 8.6 months (P = 0.849) and the median progression-free survival was 3.8 and 4.3 months (P = 0.563) for the conventional and experimental arms, respectively. Notably, the four patients who received personalized treatment had a median OS of 19.3 months.Conclusions:Personalized medicine was challenging to implement in most patients with PDAC, limiting the interpretation of intention-to-treat analysis. Survival was improved in the subset of patients who did receive matched therapy.

2025-01-16·Drug Metabolism and Personalized Therapy

Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives

Review

作者: Morón, Rocío ; Tejera-Pérez, Hugo ; Velasco-Ruiz, Alejandro ; Gil-Rodriguez, Almudena ; Apellaniz-Ruiz, Maria ; Nunez-Torres, Rocio ; Olivera, Gladys G. ; Lopez-Lopez, Elixabet ; Verde, Zoraida ; García-González, Xandra ; Castro-Sanchez, Paula ; Riera, Pau ; Muriel, Javier ; Maroñas, Olalla ; Wang, Daniel ; Comes-Raga, Ana ; Rodríguez-Vicente, Ana E. ; Sans-Pola, Carla ; Barrachina, Jordi ; Saiz-Rodríguez, Miriam ; Salvador-Martín, Sara

AbstractIntroductionPharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide.ContentThis review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice.Summary and OutlookDiverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each one with capacity to manage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.

100 项与 Centro Nacional de Investigaciones Oncologicas 相关的药物交易

登录后查看更多信息

100 项与 Centro Nacional de Investigaciones Oncologicas 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年01月31日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

2

临床前

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

AAV9-tert gene therapy (CNIO/Universitat Autonoma de Barcelona/F Hoffmann-La Roche)	心脏衰竭更多	临床前
ETP-46992 ( Class I PI3K )	肿瘤更多	临床前
IBL-100 ( PIM1 )	炎症更多	药物发现
ETP-46321 ( PI3Kα x PI3Kδ )	肿瘤更多	无进展
Salermide ( SIRT1 x SIRT2 )	肿瘤更多	无进展